Related Experiment Video
Updated: Jun 23, 2026
Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
Published on: November 6, 2021
MDM2/MDMX inhibitor peptide: WO2008106507
Antonio Macchiarulo1, Roberto Pellicciari
1Università di Perugia, Dipartimento di Chimica e Tecnologia del Farmaco, Perugia, Italy.
Background:
The evidence that some human cancers show wild-type p53 and overexpressed levels of MDM2 and/or MDMX has fueled the search for new therapeutic agents that could rescue p53 from the inhibition of MDM2 and MDMX. Recent data, suggesting a distinct and complementary mode of action of MDM2 and MDMX in the regulation of the pro-apoptotic activity of p53, have raised the notion that the development of dual or combined inhibitors of the two oncogenic proteins may result in more effective antitumor strategies.
Objective:
The objective of the present patent concerns the disclosure by two researchers of the University of South Florida, reporting a dual MDM2/MDMX inhibitor peptide that selectively blocks neoplastic growth and induces apoptosis in tumor cells.
Conclusion:
Although the researchers' results provide the proof of concept of the feasibility of blocking both MDM2 and MDMX regulatory functions for the development of novel and more incisive p53-based anticancer strategies, their invention supplies medicinal chemists with a new interesting lead compound to aid the design of novel small-molecule inhibitors of the oncogenic proteins with drug-like properties.
Insights
Researchers developed a dual MDM2/MDMX inhibitor peptide to block cancer growth. This novel peptide rescues tumor suppressor p53, offering a new strategy for p53-based anticancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Some human cancers exhibit wild-type p53 with elevated MDM2 and/or MDMX levels.
- MDM2 and MDMX inhibit the pro-apoptotic activity of p53.
- Targeting both MDM2 and MDMX may enhance antitumor strategies.
Purpose of the Study:
- To disclose a dual MDM2/MDMX inhibitor peptide.
- To selectively block neoplastic growth and induce apoptosis in tumor cells.
Main Methods:
- Peptide-based drug design targeting MDM2 and MDMX.
- In vitro and in vivo studies to assess efficacy.
Main Results:
- Demonstrated proof of concept for dual MDM2/MDMX inhibition.
- Selective blockade of tumor cell proliferation and induction of apoptosis.
Conclusions:
- Dual inhibition of MDM2 and MDMX offers a novel anticancer strategy.
- The peptide serves as a lead compound for developing small-molecule inhibitors with drug-like properties.
